

Celgene Corporation Investor Relations Department 86 Morris Avenue Summit, NJ 07901 United States

Visit IR website ☐ Sign-up for e-mail alerts ☐

NASDAQ: CELG Last Trade: 136.44 Trade Time: 4:00 PM ET Jul 25, 2017 Change: -1.40 (1.016%)Day Range 135.86 - 138.90 52-Week 96.93 - 138.93 Range Volume 3,645,465

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery. development and commercialization of innovative therapies for the treatment of cancer and immuneinflammatory related diseases. Our portfolio of commercial products include REVLIMID®. VIDAZA[®], THALOMID[®], POMALYST®/IMNOVID®. ABRAXANE®. OTEZLA® and ISTODAX[®]. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These candidates include our IMiDs... (more)

Stock Performance



Press Releases [View all]

Jul 25, 2017

<u>Celgene Corporation Announces Settlement</u> <u>of Civil Litigation</u>

Jul 5, 2017

Celgene Corporation Enters Into Global
Strategic Immuno-Oncology Collaboration
with BeiGene to Advance PD-1 Inhibitor
Program for Solid Tumor Cancers

Jul 5, 2017

Celgene Corporation to Announce Second Quarter 2017 Results on July 27, 2017

Jun 22, 2017

Celebrated Photographer Martin Schoeller
Shines a Light on People With Psoriatic
Disease Including Olympic Swimmer and
Author Dara Torres as Part of Celgene's
SHOW MORE OF YOU Campaign

Jun 19, 2017

Celgene Announces Clinical Data Evaluating
Broad Range of Blood Cancers to Be
Presented at EHA 2017

Upcoming Events [View all]

Jul 27, 2017 9:00 AM ET

Celgene Corporation Q2 2017 Celgene Corp.

Earnings Conference Call

Events [View all]

Financials [View all]

Feb 10, 2017

Annual Report (10-K)

Apr 27, 2017

Proxy Statement (DEF 14A)

Apr 27, 2017

Quarterly Report (10-Q)

Oct 27, 2016

Quarterly Report (10-Q)

Jul 28, 2016

Quarterly Report (10-Q)